Showing results (71-80 of 79) with videos related to
Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 79 results.
Blood|July 29, 1998
Presence of a p53 gene deletion in patients with multiple myeloma predicts for short survival after conventional-dose chemotherapyJ Drach, J Ackermann, E Fritz, et al.Annals of Hematology|June 10, 1998
A case of bone marrow mastocytosis associated with multiple myelomaW Hagen, J Schwarzmeier, S Walchshofer, et al.Blood|March 9, 2000
Deletion of 13q14 remains an independent adverse prognostic variable in multiple myeloma despite its frequent detection by interphase fluorescence in situ hybridizationN Zojer, R Königsberg, J Ackermann, et al.Cancer Research|March 14, 2001
Templated nucleotide addition and immunoglobulin JH-gene utilization in t(11;14) junctions: implications for the mechanism of translocation and the origin of mantle cell lymphomaN Welzel, T Le, R Marculescu, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 16, 2000
Predictive role of interphase cytogenetics for survival of patients with multiple myelomaR Königsberg, N Zojer, J Ackermann, et al.Leukemia|November 7, 2003
Diffuse large B-cell lymphomas with plasmablastic/plasmacytoid features are associated with TP53 deletions and poor clinical outcomeI Simonitsch-Klupp, I Hauser, G Ott, et al.Leukemia & Lymphoma|August 1, 2002
Serum tryptase measurements in patients with myelodysplastic syndromesW R Sperr, B Stehberger, F Wimazal, et al.Leukemia|October 3, 2009
International Myeloma Working Group molecular classification of multiple myeloma: spotlight reviewR Fonseca, P L Bergsagel, J Drach, et al.Leukemia|July 16, 2016
A randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS)R Hájek, T Masszi, M T Petrucci, et al.Pageof 8